Korean J Urol Oncol.  2022 Nov;20(4):207-222. 10.22465/kjuo.2022.20.4.207.

An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer

• Hong JH

• KMID: 2536650
• DOI: http://doi.org/10.22465/kjuo.2022.20.4.207

Abstract

Theranostics is a new term which involves the integration of therapy and diagnosis in a single platform. Prostate-specific membrane antigen (PSMA) has emerged to be a novel promising target for both diagnostic imaging and therapeutics of prostate cancer. During the past decade, radiotracers targeting the PSMA for positron emission tomography (PET) have been developed. These PET tracers are small molecular inhibitors that bind the extracellular domain of PSMA. With the recent approval of radioisotope labeled PSMA PET for clinical use, the field of PSMA theranostics has come under the spotlight. Can the preliminary efficacy and safety data on PSMA theranostics may change the prostate cancer landscape? In this review, we will focus on the history of development, approval of drug, and diagnostic and therapeutic performance of PSMA PET in patients with prostate cancer.

Keyword

Prostatic neoplasms; FOLH1 protein; Human; Radiopharmaceuticals; Positron-emission tomography